The MPTP marmoset model of Parkinsonism: A multi-purpose non-human primate model for neurodegenerative diseases

Drug Discovery Today

Volumn 15, Issue 23-24, 2010, Pages 985-990

  Philippens, Ingrid H C H M ^a,b   't Hart, Bert A ^a,c   Torres, German ^b  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b NEW YORK INSTITUTE OF TECHNOLOGY   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; APOCYNIN; CREATINE; EPIGALLOCATECHIN GALLATE; MEMANTINE; MINOCYCLINE; RASAGILINE; RILUZOLE; THIOCTIC ACID; UBIDECARENONE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG MECHANISM; EXPERIMENTAL MONKEY; HUNTINGTON CHOREA; MARMOSET; MICROGLIA; MULTIPLE SCLEROSIS; NERVE CELL LESION; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONISM; PREDICTIVE VALIDITY; PROTEIN AGGREGATION; SHORT SURVEY; STROKE;

ANIMALS; CALLITHRIX; DISEASE MODELS, ANIMAL; HUMANS; MPTP POISONING; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES; NEUROTOXINS; PARKINSONIAN DISORDERS; PRIMATES;

EID: 78649631818     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2010.08.009     Document Type: Short Survey

References (35)

1. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:787-795.
2. Beal M.F. Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann. Neurol. 2003, 53(Suppl. 3):S39-S47.
3. Petrozzi L., et al. Mitochondria and neurodegeneration. Biosci. Rep. 2007, 27:87-104.
4. Dawson T.M., Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003, 302:819-822.
5. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
6. Bonifati V., et al. DJ-1(PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol. Sci. 2003, 24:159-160.
7. Valente E.M., et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004, 304:1158-1160.
8. Gu G., et al. Mitochondrial DNA deletions/rearrangements in Parkinson disease and related neurodegenerative disorders. J. Neuropathol. Exp. Neurol. 2002, 61:634-639.
9. Cho D.H., et al. S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science 2009, 324:102-105.
10. Alexi T., et al. Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases. Prog. Neurobiol. 2000, 60:409-470.
11. Simonian N.A., Coyle J.T. Oxidative stress in neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol. 1996, 36:83-106.
12. Streit W.J., et al. Microglial degeneration in the aging brain - bad news for neurons?. Front. Biosci. 2008, 13:3423-3438.
13. Kanaan N.M., et al. Age and region-specific responses of microglia, but not astrocytes, suggest a role in selective vulnerability of dopamine neurons after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure in monkeys. Glia 2008, 56:1199-1214.
14. Barcia C., et al. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia 2004, 46:402-409.
15. Merkler D., et al. Differential macrophage/microglia activation in neocortical EAE lesions in the marmoset monkey. Brain Pathol. 2006, 16:117-123.
16. Liang X., et al. The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann. Neurol. 2008, 64:304-314.
17. Taylor J.P., et al. Toxic proteins in neurodegenerative disease. Science 2002, 296:1991-1995.
18. Gibrat C., et al. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions. J. Neurochem. 2009, 109:1469-1482.
19. Geula C., et al. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat. Med. 1998, 4:827-831.
20. Recchia A., et al. Generation of a alpha-synuclein-based rat model of Parkinson's disease. Neurobiol. Dis. 2008, 30:8-18.
21. Philippens I.H.C.H.M. Non-human primate models for Parkinson's disease. Drug Discov. Today Dis. Models 2008, 5:105-111.
22. Burn D.J. The treatment of cognitive impairment associated with Parkinson's disease. Brain Pathol. 2010, 20:672-678.
23. van Vliet S.A., et al. Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy. Brain Res. 2008, 1189:219-247.
24. LeWitt P.A. Neuroprotection for Parkinson's disease. J. Neural Transm. Suppl. 2006, 71:113-122.
25. 't Hart B.A., et al. Antiarthritic activity of the newly developed neutrophil oxidative burst antagonist apocynin. Free Radic. Biol. Med. 1990, 9:127-131.
26. Maczurek A., et al. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease. Adv. Drug Deliv. Rev. 2008, 60:1463-1470.
27. Mandel S.A., et al. Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases. CNS Neurosci. Ther. 2008, 14:352-365.
28. Koh S.H., et al. The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice. Neurosci. Lett. 2006, 395:103-107.
29. Lipton S.A. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr. Drug Targets 2007, 8:621-632.
30. Aggarwal S., Cudkowicz M. ALS drug development: reflections from the past and a way forward. Neurotherapeutics 2008, 5:516-527.
31. Obinu M.C., et al. Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence. Mov. Disord. 2002, 17:13-19.
32. McGeer P.L., McGeer E.G. Glial reactions in Parkinson's disease. Mov. Disord. 2008, 23:474-483.
33. Salińska E., et al. The role of excitotoxicity in neurodegeneration. Folia Neuropathol. 2005, 43:322-339.
34. Mattson M.P. Calcium and neurodegeneration. Aging Cell 2007, 6:337-350.
35. Gao H.M., Hong J.S. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol. 2008, 29:357-365.